{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:13:28Z","timestamp":1791976408185,"version":"4.4.0"},"reference-count":28,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2017,8,3]],"date-time":"2017-08-03T00:00:00Z","timestamp":1501718400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Federal Institute for Drugs and Medical Devices (BfArM, Germany)"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2017,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The analgesic metamizole (dipyrone) is not recommended during pregnancy due to limited experience. In several countries, metamizole has no market authorization because of agranulocytosis as a rare but severe adverse effect. However, in others, metamizole is available and widely used as a pain reliever, and its use occurs also during pregnancy, often followed by fears of potential teratogenic risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective observational cohort study compared pregnancy outcomes of 446 women exposed with metamizole in the first trimester with a randomly selected control cohort comprising 887 women not exposed to metamizole. Relevant data were obtained via structured questionnaires applied during the first trimester and 2\u00a0months after the expected date of birth between January 2000 and December 2015.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The rate of major birth defects (7\/373, 1.9%) was not increased in the metamizole cohort (OR adjusted 1.15, 95% CI 0.4\u20103.5). The cumulative incidences for spontaneous abortions did not reveal a significant difference between the exposed (12.2%, 32\/446) and comparison cohort (19.4%, 77\/887) (HR adjusted 0.72, 95% CI 0.5\u20101.1). Elective terminations of pregnancy (ETOP), mostly for \u201csocial\u201d reasons, were more frequent in the metamizole (12.5%, 45\/446) than in the comparison cohort (9.4%, 50\/887; HR adjusted 1.48, 95% CI 0.98\u20102.2).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Metamizole exposure in the first trimester does not seem to bear a substantial teratogenic risk. Our study results support reassurance in those instances where metamizole has been used during an unrecognized pregnancy or where its use appears indispensable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/pds.4277","type":"journal-article","created":{"date-parts":[[2017,8,3]],"date-time":"2017-08-03T15:35:30Z","timestamp":1501774530000},"page":"1197-1204","source":"Crossref","is-referenced-by-count":15,"title":["Metamizole use during first trimester\u2014A prospective observational cohort study on pregnancy outcome"],"prefix":"10.1002","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8674-5817","authenticated-orcid":false,"given":"Katarina","family":"Dathe","sequence":"first","affiliation":[{"name":"Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin, Humboldt\u2010Universit\u00e4t zu Berlin, and Berlin Institute of Health, Pharmakovigilanzzentrum Embryonaltoxikologie Institut f\u00fcr Klinische Pharmakologie und Toxikologie  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Padberg","sequence":"additional","affiliation":[{"name":"Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin, Humboldt\u2010Universit\u00e4t zu Berlin, and Berlin Institute of Health, Pharmakovigilanzzentrum Embryonaltoxikologie Institut f\u00fcr Klinische Pharmakologie und Toxikologie  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Hultzsch","sequence":"additional","affiliation":[{"name":"Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin, Humboldt\u2010Universit\u00e4t zu Berlin, and Berlin Institute of Health, Pharmakovigilanzzentrum Embryonaltoxikologie Institut f\u00fcr Klinische Pharmakologie und Toxikologie  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Meixner","sequence":"additional","affiliation":[{"name":"Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin, Humboldt\u2010Universit\u00e4t zu Berlin, and Berlin Institute of Health, Pharmakovigilanzzentrum Embryonaltoxikologie Institut f\u00fcr Klinische Pharmakologie und Toxikologie  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana","family":"Tissen\u2010Diabat\u00e9","sequence":"additional","affiliation":[{"name":"Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin, Humboldt\u2010Universit\u00e4t zu Berlin, and Berlin Institute of Health, Pharmakovigilanzzentrum Embryonaltoxikologie Institut f\u00fcr Klinische Pharmakologie und Toxikologie  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Meister","sequence":"additional","affiliation":[{"name":"Beuth Hochschule f\u00fcr Technik\u2014University of Applied Sciences  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelin","family":"Beck","sequence":"additional","affiliation":[{"name":"Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin, Humboldt\u2010Universit\u00e4t zu Berlin, and Berlin Institute of Health, Pharmakovigilanzzentrum Embryonaltoxikologie Institut f\u00fcr Klinische Pharmakologie und Toxikologie  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christof","family":"Schaefer","sequence":"additional","affiliation":[{"name":"Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin, Humboldt\u2010Universit\u00e4t zu Berlin, and Berlin Institute of Health, Pharmakovigilanzzentrum Embryonaltoxikologie Institut f\u00fcr Klinische Pharmakologie und Toxikologie  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,8,3]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(95)90163-9"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/uog.2647"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(97)70184-4"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200629050-00004"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(94)90073-6"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1530\/REP-17-0165"},{"issue":"14","key":"e_1_2_10_8_1","first-page":"541","article-title":"Oligoamnios associated with the use of magnesium dipyrone","volume":"104","author":"Catalan JL","year":"1995","journal-title":"Med Clin (Barc)"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfg240"},{"issue":"10","key":"e_1_2_10_10_1","first-page":"722","article-title":"Dipyrone\u2010induced oligohydramnios and ductus arteriosus restriction","volume":"8","author":"Weintraub A","year":"2006","journal-title":"Isr Med Assoc J"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.2478\/pjvs-2014-0030"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.162468699"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10787-009-0019-7"},{"key":"e_1_2_10_14_1","doi-asserted-by":"crossref","unstructured":"B\u00f6gerRH SchmidtG.Arzneiverordnungs\u2010Report 2016 Nichtopioide Analgetika. In:SchwabeU PaffrathD eds.Springer;2016:246.","DOI":"10.1007\/978-3-662-50351-5_9"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2004.07.004"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-008-0707-3"},{"key":"e_1_2_10_17_1","unstructured":"EUROCAT Complete EUROCAT guide 1.4 and reference documents (version 27.10.16). European Surveillance of congenital anomalies (EUROCAT) [2016Available from:http:\/\/www.eurocat\u2010network.eu\/aboutus\/datacollection\/guidelinesforregistration\/guide1_4"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1037\/1082-989X.9.4.403"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.reprotox.2008.06.006"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0029-1241833"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/9781119013563"},{"key":"e_1_2_10_23_1","volume-title":"Multiple Imputation for Nonresponse in Surveys","author":"Rubin DB","year":"2004"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61602-X"},{"key":"e_1_2_10_25_1","unstructured":"EUROCAT Prevalence Date Tables Cases and prevalence (per 10 000 births) of all congenital anomaly subgroups for all registries from 2010 \u2010 2014. European Surveillance of congenital anomalies (EUROCAT) last accessed 15 112016[ 2016 Available from:http:\/\/www.eurocat\u2010network.eu\/accessprevalencedata\/prevalencetables"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200730010-00006"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001648-199609000-00015"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.reprotox.2008.05.064"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.reprotox.2016.11.019"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.4277","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.4277","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T03:32:24Z","timestamp":1735788744000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.4277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,3]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["10.1002\/pds.4277"],"URL":"https:\/\/doi.org\/10.1002\/pds.4277","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,3]]}}}